In ET patients, both JAK2V617F and CALRMut bind to TPOR; JAK2V617F enhances the phosphorylation of STAT1 and STAT3 but CALRMut promotes STAT3 and STAT5 activation. Here, STAT3 is linked to essential thrombocythemia.